Anti-factor Xa Based Venous Thromboembolism Prophylaxis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-23

Study Completion Date

2021-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction: Venous thromboembolism (VTE) in the intensive care unit (ICU) is associated with significant morbidity and mortality therefore prevention is imperative to reduce its burden. VTE prophylaxis in ICU patients is primarily pharmacological using low molecular weight heparin. This study aims to determine the proportion of ICU patients receiving VTE prophylaxis that achieves appropriate anti-factor Xa activity (aFXa) prophylactic levels and to characterize this patient population Methods: Seventy-five patients admitted to the General ICU were included. Peak and trough aFXa levels were measured at 4 and 23 hours respectively after receiving the second consecutive daily enoxaparin 40 mg sc injection. Patients in whom peak aFXa levels were found to be sub-prophylactic, peak and trough levels were repeated as above

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients

NCT00351663

Venous Thrombosis Critical Illness

COMPLETED PHASE4

Thromboprophylaxis in Critically Ill Patients

NCT00437697

Venous Thromboembolism

TERMINATED PHASE4

Pharmacokinetics of Enoxaparin in Intensive Care Patients

NCT02095509

Venous Thromboembolism

COMPLETED PHASE4

Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients

NCT06357403

Thrombosis Pulmonary Embolism Enoxaparin

RECRUITING

Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

NCT02707263

Venous Thromboembolism

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dose Adjustment of Enoxaparin in ICU Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with target factor 10a levels

Patients with target factor 10a levels continued to recieve the standard Enoxaparin dose of 40 mg SC daily.

Group Type NO_INTERVENTION

No interventions assigned to this group

Patients with sub-therapuetic factor 10a levels

In patients with sub-therapuetic factor 10a levels we increased the Enoxaparin dose to 60 mg SC daily.

Group Type OTHER

Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a

Intervention Type OTHER

We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a

We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.

Intervention Type OTHER